FarmaKology -Pfizer's Covid Antiviral Appears to Work Really, Really Well

Nov 5, 2021

FarmaKology -Pfizer's Covid Antiviral Appears to Work Really, Really Well

Today's Company

Neoleukin Therapeutics

Neoleukin is a pioneer in de novo protein development, leveraging computational methods to create new therapies. This new approach has unlimited potential to treat human disease by improving on nature, designing for life. We are building a company with a vibrant and inclusive culture that we believe will make a meaningful impact for patients, our people and our community.

News

Pfizer’s Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR Study

Pfizer Inc. today announced its investigational novel COVID-19 oral antiviral candidate,PAXLOVID™, significantly reduced hospitalization and death, based on an interim analysis of the Phase 2/3 EPIC-HR (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients) randomized, double-blind study of non-hospitalized adult patients with COVID-19, who are at high risk of progressing to severe illness.

Novavax Files COVID-19 Vaccine for Emergency Use Listing with World Health Organization

Novavax, Inc., a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, announced the completion of its rolling submission to the World Health Organization (WHO) for emergency use listing of NVX-CoV2373, its COVID-19 vaccine candidate.

Ocugen, Inc. Announces Submission of Emergency Use Authorization Request to the US FDA for Investigational COVID-19 Vaccine COVAXIN™ (BBV152) for Children Ages 2-18 Years

Ocugen, Inc. , a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics and vaccines, announced today that it has submitted a request to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of Ocugen’s COVID-19 vaccine candidate BBV152, known as COVAXIN™ outside of the U.S., for pediatric use. The vaccine candidate was developed by the company’s partner, Bharat Biotech, and was studied in an immuno-bridging clinical trial conducted in India with children 2-18 years of age.

Google’s parent company launches AI-driven drug discovery start-up

Google’s parent company Alphabet has launched a new company that aims to use artificial intelligence for drug discovery, The new company, called Isomorphic Laboratories, will leverage the success of DeepMind, another Alphabet subsidiary that used AI to predict the 3D structure of a protein directly from its amino acid sequence.